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  ABSTRACT 
Abstract 
Background: Optimum transfusion strategy in patients with fractured neck of femur (NOF) is 
uncertain, particularly if there is coexisting cardiovascular disease.  
Methods: Prospective randomised feasibility trial of two transfusion strategies in a single hospital. 
We randomised patients undergoing surgery for NOF to a restrictive (haemoglobin 70-90 g.L-1) or 
liberal (Haemoglobin 90-110 g.L-1) transfusion strategy for duration of hospitalisation. Feasibility 
outcomes included: enrolment rate, protocol compliance, difference in haemoglobin and blood 
exposure. The primary clinical outcome was myocardial injury using troponin. Secondary outcomes 
included  major adverse cardiac events, postoperative complications, duration of hospitalisation, 
mortality, quality of life. 
Results: 200/907 (22% of eligible patients) were enrolled. 62 (31%) decreased haemoglobin to 90 
g.L-1 or less and were exposed to the intervention. Overall protocol compliance was 81% in the liberal 
group and 64% in the restrictive group. Haemoglobin concentrations were similar preoperatively and 
at postoperative day (POD) 1 but lower in the restrictive group at POD 2 (mean difference (MD) 7.0 
g.L-1 [95% CI 1.6, 12.4]). Lowest haemoglobin within 30 days/before discharge was lower in the 
restrictive group (MD 5.3 g.L-1 [95% CI 1.7, 9.0]). 58% of patients in the restrictive group received no 
transfusion compared with 4% in the liberal group (difference in proportion 54.5% [95% CI 36.8%, 
72.2%]). The proportion with the primary clinical outcome was 14/26 (54%, liberal) vs 24/34 (71%, 
restrictive), difference in proportion -16.7% [95% CI -41.3%, 7.8%] p=0.182. 
Conclusion: A study of two transfusion strategies with a clinically relevant cardiac outcome is 
feasible. 
Trial Registration: Clinical trials NCT03407573 
  
INTRODUCTION 
Epidemiological studies suggest that patient co-morbidities, including anaemia, are associated with 
increased rates of complications and death following surgery.1–3 Anaemia either may reflect the 
severity of chronic disease or be the result of blood loss from injury or surgery, and may not have a 
causative relationship with poor outcomes. Patients commonly receive red cell transfusions to 
increase haemoglobin concentration with the belief that this may increase oxygen delivery to the 
tissues, particularly to the myocardium and improve clinical outcomes. Blood transfusion is 
associated with risks including fluid overload, immunosuppression and consequent risks of infectious 
complications and cancer recurrence.4–8 Donated blood is also a finite and costly resource. 
Evidence generally supports restrictive transfusion strategies (i.e. a transfusion trigger of 70 g.L-1) in 
stable hospitalized adult patients,9 but the optimum transfusion threshold for surgical patients 
remains uncertain, particularly if there is coexisting cardiovascular disease (CVD).10  The need for 
more evidence is highlighted in recommendations from the National Institute of Clinical Excellence 
(NICE) and the Association of Anaesthetists. Both these guidelines recommend a restrictive 
transfusion practice, using 70 g.L-1 as the default threshold, but recommend caution and highlight 
that higher thresholds might be considered for patients with CVD. NICE recommended further 
research in this area was a priority.11  
People undergoing surgery for fractured neck of femur (NOF) are often frail and elderly with multiple 
comorbidities,12 including perioperative anaemia from fracture or surgery-induced bleeding.3,13,14 
There is a high prevalence of pre-existing cardiovascular disease (CVD) in this population15,16 and 
red cell transfusions are typically prescribed to prevent cardiac complications, improve mobilisation 
and reduce length of hospitalisation.17–20 Concerns exist that current practice guidelines may be 
inadequate in this setting. Findings of a recent Cochrane review of transfusion strategy in patients 
with hip fracture did not find evidence to support a liberal transfusion strategy but conceded that the 
overall quality of the evidence was low.21 The largest study of transfusion strategy in this population 
used higher liberal and restrictive targets which were less relevant to current practice.22 A recent UK 
survey suggested wide variation in perioperative transfusion practice among anaesthetists, surgeons 
and perioperative physicians23 and a need for further studies to identify the optimum transfusion 
threshold in the perioperative period, particularly if there is coexisting CVD. The latest generation of 
cardiac troponin assays can detect myocardial necrosis with a high degree of precision and when 
measured following surgery the presence of necrosis correlates strongly with adverse outcomes.24 
Isolated postoperative elevations in troponin without symptoms or other clinical signs have similar 
associations with mortality as myocardial infarction (MI) which fulfils universal diagnostic criteria.  
We conducted a prospective feasibility study of two red cell transfusion strategies in people admitted 
to hospital following a fractured NOF. The study aims were twofold: 
1. To investigate the feasibility, in terms of recruitment, protocol compliance and red cell 
transfusion, of conducting a randomised trial of liberal versus restrictive transfusion in 
patients with fractured NOF. 
2. To investigate the effect of transfusion strategy on the clinical outcomes of myocardial injury, 
other postoperative complications, mortality, duration of hospitalisation, quality of life. 
 
METHODS 
Trial design and oversight 
RESULT-NOF was a feasibility study of an open randomised trial of two transfusion strategies in 
people undergoing surgery for fractured NOF, conducted in a single NHS hospital in the United 
Kingdom. The study protocol was approved by a Scotland A Research Ethics Committee 
(Reference:17/SS/0053) and registered with ClinicalTrials.gov (NCT03407573). Written consent was 
obtained from all study participants or if they lacked capacity, their nearest relative or welfare 
attorney, in accordance with Scots Law. NHS Lothian and the University of Edinburgh acted as co-
sponsors of the study (www.accord.scot). An independent data and safety committee met three 
times during the course of the study to review study outcomes. 
 
Participants 
People aged 50 years or older, within 48 hours of admission to the Royal Infirmary of Edinburgh 
(RIE) with a fractured NOF, and who had not yet undergone surgery met inclusion criteria for 
enrolment to this study. Those who were receiving palliative care, who had received a blood 
transfusion prior to recruitment in same hospital admission or who declined to give consent were 
excluded. Potential participants were identified directly from the orthopaedic wards, via daily 
screening of theatre lists, or transfers from the RIE Emergency Department (ED).  
Randomisation 
Participants were randomised 1:1 to either a restrictive or liberal transfusion strategy for the duration 
of their hospital stay or 30 days, whichever was sooner. A secure electronic internet-based 
randomisation system was used with a dynamically allocated block list (block sizes 4 and 6). The 
patient’s clinical team and the hospital blood transfusion laboratory were informed of the patient’s 
study status by the study team, having been concealed until that point, and that they were to be 
transfused according to the study protocol. 
Study Procedure 
 
Patients were enrolled preoperatively. A restrictive strategy was defined as a haemoglobin 
transfusion trigger of 70 g.L-1 or less and a target haemoglobin range of 70-90 g.L-1. This was the 
target haemoglobin range recommended by UK guidelines. A liberal strategy was defined as a 
haemoglobin transfusion trigger of 90 g.L-1 or less and a target haemoglobin range of 90-110 g.L-1. 
It was recommended that participants requiring transfusion should be transfused one unit of red 
blood cells and the haemoglobin rechecked until within the target range (Electronic Supplementary 
Material, ESM). Physicians were able to transfuse participants in emergency or life-threatening 
situations e.g. major haemorrhage. In these situations, the protocol was temporarily suspended until 
the situation was resolved and recorded as a protocol deviation. 
 
At enrolment we collected baseline demographic data: age, sex, ethnicity, cardiovascular risk 
factors, pre-admission cardiac medications, Charlson Comorbidity Index, and ASA Physiological 
Status (ASA) classification. Cardiac risk factors were defined prospectively as a pre-existing 
diagnosis of the following: ischaemic heart disease, peripheral vascular disease, cerebrovascular 
disease, age over 65 years, diabetes, hypertension or other cardiac disease.  
Baseline haemoglobin measurement, plasma cardiac troponin I (cTnI) concentrations 
(ARCHITECTSTAT, Abbott Laboratories, Abbott Park, Illinois, USA) and a 12-lead electrocardiogram 
(ECG) were also performed.  
 
Type of surgery, anaesthesia, surgical duration, and postoperative destination were recorded upon 
completion of surgery. Haemoglobin concentration measurement was made immediately after 
surgery in the recovery room using the HemoCue® Haemoglobin 201+ system (HemoCue AB, 
Angelholm, Sweden). Further laboratory haemoglobin sampling was taken on postoperative days 
(POD) one and two then thereafter at the discretion of the clinical team. A further ECG was performed 
on POD 3. Blood samples were drawn by venepuncture into a vacuum tube and subsequently 
analysed in the central NHS laboratory.  
 
The study cohort of interest was those participants whose haemoglobin fell below a threshold 
haemoglobin of 90 g.L-1 or less during their hospital admission as only these participants were 
exposed to the study intervention. From the time that an enrolled patient’s haemoglobin dropped to 
90 g.L-1 or less, we measured troponin and haemoglobin on the first, second and fifth day thereafter. 
Blood sampling and full outcome data were only collected in these participants, however basic 
demographic and outcome data were collected for all participants enrolled. Serum troponin 
measurements taken solely for the purpose of this research study were suppressed from clinical 
staff. A cardiology and an anaesthesia specialist trainee, interpreted all ECGs after recruitment was 
completed. Dynamic ischaemic ECG changes were considered either as new or progressive ECG 
changes consistent with ischaemia between admission to the third postoperative day. 
 
Number and volume of blood transfusion, complications, and death within 30 days following surgery 
or before acute hospital discharge (whichever was sooner) were recorded. Participants were also 
contacted at 60 days following surgery to assess vital status and quality of life using the EuroQoL 
EQ-5D tool. 
 
All data were entered directly onto a secure, trial specific database using REDCap: Research 
Electronic Data Capture (Vanderbilt University, USA). This is a secure, fully-audited password 
protected platform, hosted on University of Edinburgh servers. All identifiable data were removed 
before extraction for analysis.  
 
Blinding 
The clinical and research teams were not blinded to the intervention but were blinded to the primary 
outcome. The study statistician analysed data blinded from group allocation. The adjudicators who 





The feasibility outcomes were proportion of eligible patients recruited; protocol compliance; 
haemoglobin concentration distribution within 3 and 30 days of surgery (including nadir 
haemoglobin); red blood cell use within 5 days of anaemia, and within 30 days of surgery or hospital 
discharge). Three protocol deviations were prospectively defined as transfusion of red blood cells 
above the predefined transfusion trigger, transfusion without checking haemoglobin level and 




The primary outcome was postoperative myocardial injury defined as any serum cTnI concentration 
above the upper reference limit (URL) during the study period, measured using the ARCHITECTSTAT 
high-sensitive troponin I assay (Abbott Laboratories, Abbott Park, IL, USA). The assay has a limit of 
detection of 1.2 ng.L−1 and an interassay coefficient of variation of <10% at 4.7 ng.L−1. The mean 
(SD) concentration for a healthy reference population is 1.6 (3.1) ng.L−1, and the 99th percentile upper 
reference limit (URL) for the whole population is 16 ng.L-1 and 34 ng.L-1 for women and men 
respectively.25,26   
Secondary outcomes were mortality at 30 and 60 days, acute kidney injury (KDIGO definition), 
delirium, myocardial infarction (universal definition), major adverse cardiac events (MACE) and 
postoperative complications. Definitions for postoperative complications are supplied in the ESM. 
Other measured outcomes included: peak troponin concentration, area under a troponin-time curve, 
nadir haemoglobin within 30 days (or hospital discharge), hospital length of stay, discharge 
destination, hospital readmission and EQ-5D at 60 days.  
 
Statistical Analysis 
While no formal power calculation was made, it was estimated that 600 patients would be eligible for 
recruitment annually based on admission statistics to the RIE. Assuming a 50% refusal rate, a 
realistic target of 200 participants over a one year period was established.  
The statistical analysis was performed based on a pre-specified analysis plan. Continuous data were 
presented as mean (95% confidence interval [CI]), or median (interquartile range [IQR]) if non-
normally distributed. Binary data were presented as frequency (%). Feasibility outcomes were 
reported as a difference between groups with corresponding 95% CIs. Primary and secondary 
clinical outcomes were compared using a chi-squared or Fisher’s exact test as appropriate and 
presented as a difference in proportions with corresponding 95% CIs. All analyses were based on a 
modified intention to treat (ITT) principle:  we included all participants randomised into the RESULT-
NOF study who become anaemic (haemoglobin 90 g.L-1 or less) during their treatment (and thus 
were exposed to the study intervention) and for whom outcome data was available. To assess the 
impact of missing follow-up cTnI measurements on the primary outcome, a sensitivity analysis was 
performed where those who did not have the primary outcome but had at least one follow-up cTnI 
measurement missing were classified as having myocardial injury. Finally, an exploratory analysis 
was undertaken where the universal definitions applied to diagnose Type 2 myocardial infarction 
(MI) or myocardial injury, including a rise and fall in troponin were applied.27 All analyses were 
performed using SAS version 9.4. 
 
RESULTS 
The study enrolment period ran from 1st November 2017 until the 31st January 2019 when the 200th 
participant was recruited. Final patient follow-up was completed on the 31st April 2019.  
Participants 
A flowchart summarising patient recruitment is outlined in Figure 1. 1,041 patients were screened, 
907 were eligible for recruitment and 200 (22%) participants were enrolled in the study. Of 200 
participants, Sixty-two (31%) dropped their haemoglobin to 90 g.L-1or less and were therefore 
exposed to the study intervention: 26 allocated to liberal and 36 to restrictive groups. All participants 
went on to have surgery, reflecting current practice. Baseline patient characteristics are reported in 
Table 1. There was a higher prevalence of cardiovascular risk factors in participants who became 
anaemic compared to those who did not.  
Outcomes 
Feasibility Outcomes 
Feasibility outcomes are reported in Table 2. From 907 patients eligible for recruitment, 200 (22%) 
were recruited. Overall protocol compliance was 81% in the liberal group and 64% in the restrictive 
group. There was greater compliance to transfusion of red blood cells within the predefined trigger 
in the liberal compared to the restrictive group (Difference 25.6% [95% CI 7.1%, 44.1%]). Of the 18 
participants transfused off-protocol, five were transfused in response to excessive bleeding in theatre 
and one was transfused in error after blood was prescribed for the wrong patient. There was minimal 
differences in haemoglobin concentration between liberal and restrictive groups preoperatively and 
at POD 1 with a larger difference at POD 2 (mean difference 7.0 g.L-1 [95% CI 1.6, 12.4], Table 2. 
Figure 2. Supplementary Figure 2.). Lowest haemoglobin was lower in the restrictive group within 3 
days of surgery (mean difference 3.1 g.L-1 [95% CI -1.8, 8.0]) and within 30 days of surgery/hospital 
discharge (mean difference 5.3 g.L-1 [95% CI 1.7, 9.0]). There was a difference in blood use between 
groups; 58% of participants in the restrictive group received no transfusion within 30 days of 
surgery/hospital discharge compared with only 4% in the liberal group (difference in proportions 
54.5% [95% CI 36.8%, 72.2%]). 
 
Primary Outcome 
Patient outcomes are summarised in Table 3. There was no statistically significant difference in the 
proportion of participants with the primary outcome, (54% in the liberal group vs 71% in the restrictive 
group, mean difference -16.7% [95% CI -41.3%, 7.8%] p=0.182) or in the sensitivity analysis 
accounting for missing data. In the exploratory analysis using the universal definition of MI, the 
overall incidence of cardiac injury was smaller but with a similar pattern observed between groups 
(31% liberal vs 53% restrictive, mean difference -22.2% [95% CI -46.6%, 2.2%] p=0.086) (Table 3).  
 
In those compliant with the protocol, 12/21 (57%) had the primary outcome in the restrictive arm and 
12/21 (57%) in the liberal arm. Difference in proportions was 0.0% (-29.9% to 29.9%). We  undertook 
a non-prespecified, post-hoc, per-protocol analysis which did not demonstrate any difference in the 
primary outcome (p-value=1.0). 
 
Secondary Outcomes 
The rate of ECG abnormalities was high: 57% in the liberal group vs. 59% the restrictive group, 
however only one myocardial infarction was diagnosed clinically in participants exposed to the 
intervention in the restrictive group. Rates of clinically diagnosed MACE were lower in the liberal 
(8%) compared to the restrictive (19%) group (difference in proportion -11.8% [95% CI -28.2%, 4.7%] 
p=0.282) but did not reach significance. There were no differences in other secondary clinical 
outcomes or mortality between groups (Table 3). 
 
Safety Data 
The rate of serious adverse events (SAE) was high in this group of patients with 15% (30/200) of 
patients suffering at least one or more SAE. Only one was possibly related to the study procedures, 
an episode of transfusion related circulatory overload (TACO) in the restrictive group. 
  
DISCUSSION 
This study found that recruitment to a randomised trial of two transfusion strategies in a population 
of patients with a high prevalence of cardiovascular and other comorbidities was feasible. Separation 
of groups by both haemoglobin concentration and blood usage was also demonstrated. Protocol 
compliance suggested that due to clinical reasons and clinician beliefs, there was a difference in the 
rate of protocol deviations between liberal and restrictive groups, with a higher non-compliance rate 
in the restrictive arm. Use of a primary outcome based on detection of myocardial infarction or injury 
using high sensitivity troponin assay, measured after patients became anaemic, was also feasible. 
Although this study was not powered to detect a difference in clinical outcomes between groups, 
findings suggested a signal for an increased rate of myocardial injury associated with restrictive 
transfusion strategies, although it should be noted that the rate of pre-existing ischaemic heart 
disease was not evenly distributed between the groups (Table 1). 
Concerns regarding the potential effect of severe anaemia on cardiac injury remain. A large study of 
two transfusion strategies in 2000 patients with fractured NOF published in 2011 did not show a 
difference in a composite primary outcome of death or inability to walk unassisted across a room at 
60 days.22 This study reported the rate of acute coronary syndrome as a secondary outcome and 
observed no difference between groups. However, more recent systematic reviews of transfusion 
strategy in surgical patients have suggested that restrictive strategies are associated with increased 
rates of MI or MACE, particularly if there is pre-existing cardiac disease 28,29 and in patients 
undergoing surgery for fractured NOF.30 One possible explanation is that the restrictive and liberal 
strategy used in earlier studies does not reflect current practice, which would consider a restrictive 
strategy to maintain haemoglobin between 70 and 90 g.L-1 and a liberal strategy at between 90 and 
110 g.L-1. A clinician survey undertaken in the UK by our group suggests continued uncertainty in 
managing anaemia in this group, particularly in the setting of cardiac disease.23 Our findings are 
consistent with other recent trial data, including a small trial in vascular surgery and in transfusion-
dependent patients with myelodysplasia which identified improvements in quality of life domains for 
participants in the liberal compared to restrictive arm.31 
Other findings of our study were a high rate of co-existing cardiovascular disease in this group, 
especially in those who were severely anaemic. This may account for protocol deviations among 
participants randomised to a restrictive strategy and may have represented clinical concern among 
clinicians, particularly as patient’s haemoglobin levels fell close to the restrictive trigger of 70 g.L-1. 
Our study also suggested a high rate of postoperative cardiac complications in this group, particularly 
when modern high sensitivity troponin assays are used routinely.  
Strengths of this study are that it was a large feasibility trial that recruited within the planned 
timeframe, with low rates of missing data or participants lost to follow up. Participants in the liberal 
transfusion group had significantly higher exposure to blood and there was a mean difference in 
haemoglobin following POD 2, despite some issues with protocol compliance. High rates of cardiac 
complications and mortality suggest these would be patient centred outcomes which could be 
studied in a future trial. 
There were several weaknesses in the design which could be addressed in a refined protocol for a 
larger study. Firstly, 58% of eligible participants could not be recruited as they had already 
undergone surgery before the study team was able to approach them. This probably reflects quality 
improvement initiatives to expedite surgery and minimise the delay in operating on this group. It is 
possible that the more severely injured patients, and hence those with the greatest blood loss were 
excluded from the study for this reason, explaining the lower than anticipated rate of anaemia 
observed in this study. In this group there are high rates of cognitive impairment (both acute and 
pre-existing) necessitating the need for proxy consent and introducing a further delay. Strategies to 
identify and recruit patients at an earlier stage in their inpatient admission could address these 
issues. The optimal transfusion threshold in older patients may also be different and a future study 
should include a prespecified subgroup of older patients. 
Although groups were balanced at the point of randomisation, only those who became anaemic (i.e. 
haemoglobin falling to 90 g.L-1or less) were exposed to the study intervention and were part of the 
intention-to-treat analysis population which resulted in some imbalance in patient characteristics in 
the restrictive and liberal groups. This study design has been used in previous studies of transfusion 
strategy and we believe the imbalance between groups would have resolved with a larger sample 
size. A retrospective analysis of study data suggested that restricting recruitment to patients who 
were already anaemic (e.g. haemoglobin of 110 g.L-1 or less) would not have enriched the 
recruitment of patients whose haemoglobin later fell to 90 g.L-1or less.  
Finally, protocol compliance is an area which would need be improved in a larger study. The overall 
compliance of 70% observed in this study is would need to be improved in a larger study. In studies 
of transfusion practice some protocol deviations are inevitable as the protocol must be suspended 
in episodes of major haemorrhage. As many of these deviations occurred in the perioperative period 
restricting the study intervention to the postoperative period, could improve this. Clinician focus 
groups may also be useful to identify how the protocol could be adapted to improve adherence over 
an often protracted hospital stay with multiple clinical teams involved.  
Hip fracture is the most common serious injury in older people. Our study confirms that elderly 
patients having surgery for hip fracture have a high rate of pre-existing cardiac disease and 
postoperative cardiac events, including troponin release. There is a high rate of anaemia and blood 
transfusion in this population and the optimum transfusion threshold is not known. A larger study of 
liberal versus restrictive transfusion practice with a clinically relevant cardiac outcome in this 
population is warranted and is feasible in a National Health Service hospital setting. The future 
design of such a trial could be informed by the findings of this study. Based on our experience, we 
would suggest that patients who drop their haemoglobin to 90 g.L-1 or less postoperatively are the 
ideal study population. There is a significant incidence of mental incapacity in people with hip fracture 
which make recruitment and consent challenging. We suggest that a suitable primary outcome for 
such a study could be death or major adverse cardiac events within 30 days of surgery, to address 
the existing clinical controversy around cardiovascular complications. However, it is also important 
to measure the impact of transfusion practice on quality of life at hospital discharge and beyond. 
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